Related Articles
Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery
Lentiviral delivery of CTLA‑4 shRNA improves the expansion of cytokine‑induced killer cells and enhances cytotoxic activity in vitro
A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment
CTLA‑4 blockade combined with 5‑aza‑2'‑deoxycytidine enhances the killing effect of MAGE‑A family common antigen peptide‑specific cytotoxic T cells on breast cancer
Molecular characteristics of breast cancer according to clinicopathological factors